kras

Documents about kras

• JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration#1353165ClinicalTrials.gov
• A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration#1212338ClinicalTrials.gov
• Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma#249613ClinicalTrials.gov
• A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors#234504ClinicalTrials.gov
• TLN-372 in Advanced KRAS Mutant Solid Tumors#1293531ClinicalTrials.gov
• TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors#892353ClinicalTrials.gov
• CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors#332808ClinicalTrials.gov
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer#1072585ClinicalTrials.gov
• A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations#838499ClinicalTrials.gov
• Studying Pathways of Resistance in KRAS-driven Cancers#854674ClinicalTrials.gov
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer#1057949ClinicalTrials.gov
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer#1031547ClinicalTrials.gov
• A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors#907054ClinicalTrials.gov
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors#1363233ClinicalTrials.gov
• A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients#1197115ClinicalTrials.gov
• Biomarker - Panitumumab Response With KRAS Wild Type MCC#1464054ClinicalTrials.gov
• Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations#993142ClinicalTrials.gov
• Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.#1075515ClinicalTrials.gov
• A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors#1365628ClinicalTrials.gov
• Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors#201612ClinicalTrials.gov
• Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer#1323573ClinicalTrials.gov
• Targeting WFS1 overcomes KRAS(G12D) dependency and adaptive resistance to KRAS inhibition in pancreatic cancer.#298906NCBI PubMed Central
• Mechanisms of response and resistance to KRAS inhibition in pancreatic cancer#347596Harvard DASH
• Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis#215395HAL (France)
• A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.#863551ClinicalTrials.gov
• Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations#1440402ClinicalTrials.gov
• A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation#843941ClinicalTrials.gov
• Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors#1310296ClinicalTrials.gov
• KRAS, NRAS and BRAF Mutational Landscape in Serbian Early-Onset Colorectal Cancer Patients#237861Zenodo (CERN)
• Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors#426642ClinicalTrials.gov
• Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.#967257ClinicalTrials.gov
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1#910648ClinicalTrials.gov
• Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation#1378580ClinicalTrials.gov
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors#803150ClinicalTrials.gov
• KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors#414486ClinicalTrials.gov
• Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations#833525ClinicalTrials.gov
• A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours#1033635ClinicalTrials.gov
• A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation#1377454ClinicalTrials.gov
• A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation#1419380ClinicalTrials.gov
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors#1496794ClinicalTrials.gov
• Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases#1100862ClinicalTrials.gov
• Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC#1370721ClinicalTrials.gov
• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer#855256ClinicalTrials.gov
• RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer#1261277ClinicalTrials.gov
• A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration#1337508ClinicalTrials.gov
• Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies#1430700ClinicalTrials.gov
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors#1009508ClinicalTrials.gov
• Targeted therapy in pancreatic ductal adenocarcinoma: current advances and challenges#667087ULRR
• IRE1alpha–XBP1s signaling links lipid homeostasis to hypoxic maladaptation and KRAS inhibitor responses in pancreatic ductal adenocarcinoma#929192ScholarlyCommons
• HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation#1044899ClinicalTrials.gov